Scotiabank raised the firm’s price target on UroGen Pharma (URGN) to $47 from $23 and keeps an Outperform rating on the shares. The firm is increasing its FDA approval likelihood from 60% to 100% and raised its price target based on its current view of a peak ZUSDURI market opportunity of about $1B, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: